10 results on '"Jonathan Lopez"'
Search Results
2. Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors
- Author
-
Romain Varnier, Alicja Puszkiel, Michel Tod, Sara Calattini, Lea Payen, Jonathan Lopez, Jérome Guitton, Vérane Schwiertz, Juliette Fontaine, Julien Peron, Denis Maillet, Sophie Tartas, Nathalie Bonnin, Olivier Colomban, Diane Augu-Denechere, Gilles Freyer, and Benoit You
- Subjects
Pharmacology ,Cancer Research ,Oncology ,Pharmacology (medical) ,Toxicology - Published
- 2023
3. CREB fusion–associated epithelioid mesenchymal neoplasms of the female adnexa: three cases documenting a novel location of an emerging entity and further highlighting an ambiguous misleading immunophenotype
- Author
-
Alexis Trecourt, Nicolas Macagno, Carine Ngo, Charles-André Philip, Jonathan Lopez, Joana Ferreira, Catarina Alves-Vale, Isabelle Ray-Coquard, Catherine Genestie, Abbas Agaimy, and Mojgan Devouassoux-Shisheboran
- Subjects
Cell Biology ,General Medicine ,Molecular Biology ,Pathology and Forensic Medicine - Abstract
EWSR1/FUS-CREB-rearranged mesenchymal neoplasms are an emerging heterogeneous group of soft tissue tumors that encompasses low-grade lesions (angiomatoid fibrous histiocytoma/AFH) and a group of predominantly intra-abdominal aggressive sarcomas with epithelioid morphology and frequent keratin expression. Both entities occasionally harbor EWSR1::ATF1 fusions as alternate to the more frequent EWSR1/FUS::CREB1/CREM fusions. Although EWSR1/FUS-CREB-rearranged epithelioid malignant neoplasms have been described in diverse intra-abdominal sites, none involved the female adnexa. Herein, we describe three cases involving uterine adnexa in young females (41, 39, and 42-year-old); two associated with constitutional inflammatory symptoms. The tumors presented as a serosal surface mass of the ovary without parenchymal involvement (Case 1), as circumscribed nodule within ovarian parenchyma (Case 2), and as a periadnexal mass extending into the lateral uterine wall with lymph node metastasis (Case 3). They were composed of sheets and nests of large epithelioid cells with numerous stromal lymphocytes and plasma cells. The neoplastic cells expressed desmin and EMA, and variably WT1. One tumor expressed in addition AE1/AE3, MUC4, synaptophysin, chromogranin, and ALK. None expressed sex cord-associated markers. RNA sequencing identified EWSR1::ATF1 fusions in two cases and an EWSR1::CREM fusion in one. Exome-based RNA capture sequencing and clustering methods showed high transcriptomic proximity of tumor 1 with soft tissue AFH. This novel subset of female adnexal neoplasms should be included in the differential diagnosis of any epithelioid neoplasm involving female adnexa. Their aberrant immunophenotype can be misleading, underlining a wide spectrum of differential diagnosis.
- Published
- 2023
4. Comparing the Efficiency of Online and Field-Based Outreach for the Recruitment of Black and Latino Sexual Minority Men into an HIV Prevention Implementation Trial
- Author
-
Jesse Bradford-Rogers, Jonathan Lopez-Matos, Demetria Cain, David Lopez, and Tyrel J. Starks
- Subjects
Male ,Acquired Immunodeficiency Syndrome ,Patient Selection ,Ethnicity ,Public Health, Environmental and Occupational Health ,Humans ,HIV Infections ,Hispanic or Latino ,Homosexuality, Male ,Minority Groups - Abstract
Rates of HIV diagnoses among young Black and Latino sexual minority men (SMM) have continued to increase since 2011; meanwhile, overall rates in the USA have decreased. Despite their importance, academic and medical institutions have often struggled to engage and recruit racial and ethnic minority SMM in HIV prevention services and research. The current study compares the success of two strategies for recruiting racial and ethnic minority SMM. Recruitment occurred in the context of a larger implementation study testing the effectiveness of a substance use and HIV prevention intervention among SMM at high risk for HIV infection. SMM (n = 778) were reached through either (1) field-based outreach conducted by two local community-based organizations (CBOs) delivering the intervention or (2) online recruitment coordinated by the trial's academic research partner. Field-based recruitment reached a significantly larger proportion of Black (42.9% vs. 18.2% reached online) and Latino individuals (40.3% vs. 28.1% reached online). Although online recruitment reached a greater proportion of SMM who met trial eligibility criteria (58.4% vs. 35.3% for field-based outreach; χ
- Published
- 2022
5. Poorly differentiated thyroid carcinoma with pleomorphic giant cells—a case report
- Author
-
Jonathan Lopez, Manuel Sobrinho-Simões, Christine Cugnet-Anceau, M. Decaussin-Petrucci, J.C. Lifante, Alexia Gazeu, and Serge Guyétant
- Subjects
0301 basic medicine ,Capsular Invasion ,Pathology ,medicine.medical_specialty ,business.industry ,Thyroid ,Cell Biology ,General Medicine ,medicine.disease_cause ,medicine.disease ,Pathology and Forensic Medicine ,Thyroid carcinoma ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Poorly Differentiated Thyroid Carcinoma ,Giant cell ,030220 oncology & carcinogenesis ,Carcinoma ,Medicine ,Immunohistochemistry ,business ,Molecular Biology ,Thyroid neoplasm - Abstract
Poorly differentiated thyroid carcinoma (PDTC) refers to a malignant tumour that displays an intermediate prognosis between well-differentiated carcinomas and anaplastic thyroid carcinomas (ATC). In the thyroid, pleomorphic giant cells are observed in ATC or in some non-neoplastic thyroid diseases. We described the case of a 43-year-old woman with a 34-mm nodule in her thyroid right lobe. Microscopic examination revealed an encapsulated tumour with a main solid growth pattern and extensive capsular invasion. Multiple images of angioinvasion were observed. There was neither necrosis nor inflammation. Most of the tumour cells were medium-sized and intermingled with pleomorphic giant tumour cells with bizarre features. The immunoprofile (keratins +, TTF1+, Pax 8+) proved their thyroid origin. By NGS, no molecular alteration was identified. The patient was treated by surgery and radioiodine therapy and she has no recurrence after a follow-up of 24 months. Our case meets all the histological criteria of the Turin proposal for PDTC but with pleomorphic giant cells and is very different from ATC according to clinical, histological and immunohistochemical features. Pleomorphic tumour giant cells in thyroid carcinomas could be present in PDTC and do not always represent dedifferentiation and more aggressive carcinoma, thyroid neoplasm.
- Published
- 2020
6. A classification of small operators using graph theory
- Author
-
Jonathan Lopez and Terrence Bisson
- Subjects
Spectral radius ,History and Overview (math.HO) ,Mathematics - History and Overview ,General Mathematics ,010102 general mathematics ,Coxeter group ,Graph theory ,Disjoint sets ,01 natural sciences ,010305 fluids & plasmas ,Combinatorics ,Matrix (mathematics) ,Computational Theory and Mathematics ,0103 physical sciences ,Lie algebra ,FOS: Mathematics ,Bipartite graph ,Mathematics - Combinatorics ,Combinatorics (math.CO) ,05C50, 15A60, 15B36, 17B20, 17B22, 20F55 ,0101 mathematics ,Statistics, Probability and Uncertainty ,Operator norm ,Mathematics - Abstract
Given a real $n \times m$ matrix $B$, its operator norm can be defined as $$|B|=\max_{|v|=1}|Bv|.$$ We consider a matrix "small" if it has non-negative integer entries and its operator norm is less than $2$. These matrices correspond to bipartite graphs with spectral radius less than $2$, which can be classified as disjoint unions of Coxeter graphs. This gives a direct route to an $ADE$-classification result in terms of very basic mathematical objects. Our goal here is to see these results as part of a general program of classification of small objects, relating quadratic forms, reflection groups, root systems, and Lie algebras., 16 pages, the main goal of this paper is to exposit a self-contained ADE-classification result that requires minimal background
- Published
- 2018
7. Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency
- Author
-
Andrew Oberst, Karen Blyth, Alba Roca, Nader Yatim, Simon Milling, Laura M. Machesky, Barbara Zunino, Matthew L. Albert, Camila Rubio-Patiño, Stephen W.G. Tait, Nieves Peltzer, Loic Fort, Kai Cao, Emma Proïcs, Jonathan Lopez, Sandeep Dhayade, Florian J. Bock, Gabriel Ichim, Daniele Lecis, Jean-Ehrland Ricci, Catherine Cloix, Lucia Taraborrelli, Susana Orozco, Emma F. Woodham, Kevin M. Ryan, Evangelos Giampazolias, and Henning Walczak
- Subjects
0301 basic medicine ,Programmed cell death ,biology ,Effector ,NF-kappa B ,Apoptosis ,Cell Biology ,Mitochondrion ,Inhibitor of apoptosis ,Article ,Mitochondria ,3. Good health ,Cell biology ,03 medical and health sciences ,RIPK1 ,030104 developmental biology ,Caspases ,Neoplasms ,Cancer cell ,biology.protein ,Humans ,Caspase - Abstract
Apoptosis represents a key anti-cancer therapeutic effector mechanism. During apoptosis, mitochondrial outer membrane permeabilisation (MOMP) typically kills cells even in the absence of caspase activity. Caspase activity can also have a variety of unwanted consequences that include DNA-damage. We therefore investigated whether MOMP-induced caspase-independent cell death (CICD) might be a better way to kill cancer cells. We find that cells undergoing CICD display potent pro-inflammatory effects relative to apoptosis. Underlying this, MOMP was found to stimulate NF-κB activity through the down-regulation of inhibitor of apoptosis (IAP) proteins. Strikingly, engagement of CICD displays potent anti-tumorigenic effects, often promoting complete tumour regression in a manner dependent on intact immunity. Our data demonstrate that by activating NF-κB, MOMP can exert additional signalling functions besides triggering cell death. Moreover, they support a rationale for engaging caspase-independent cell death in cell-killing anti-cancer therapies.
- Published
- 2017
8. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine
- Author
-
Florence Geiguer, Norelyakin Kara, Françoise Descotes, Jonathan Lopez, Eric Piaton, Myriam Decaussin-Petrucci, Jean E Terrier, Claire Rodriguez-Lafrasse, and Alain Ruffion
- Subjects
Adult ,Male ,non-invasive prognostic marker ,Cancer Research ,Pathology ,medicine.medical_specialty ,Neoplasm, Residual ,recurrence ,TERT ,030232 urology & nephrology ,Urology ,Urine ,Genetics & Genomics ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Cytology ,Carcinoma ,Humans ,cystoscopy ,Medicine ,Telomerase reverse transcriptase ,Prospective Studies ,Promoter Regions, Genetic ,Telomerase ,Aged ,Urine cytology ,Aged, 80 and over ,Carcinoma, Transitional Cell ,Univariate analysis ,transurothelial bladder resection ,Bladder cancer ,medicine.diagnostic_test ,business.industry ,Carcinoma in situ ,Cystoscopy ,Middle Aged ,medicine.disease ,Urinary Bladder Neoplasms ,Oncology ,Population Surveillance ,030220 oncology & carcinogenesis ,Mutation ,cytology ,urothelial bladder cancer ,Female ,Neoplasm Recurrence, Local ,business - Abstract
Background: Urothelial bladder cancer (UBC) is characterised by a high risk of recurrence. Patient monitoring is currently based on iterative cystoscopy and on urine cytology with low sensitivity in non-muscle-invasive bladder cancer (NMIBC). Telomerase reverse transcriptase (TERT) is frequently reactivated in UBC by promoter mutations. Methods: We studied whether detection of TERT mutation in urine could be a predictor of UBC recurrence and compared this to cytology/cystoscopy for patient follow-up. A total of 348 patients treated by transurethral bladder resection for UBC were included together with 167 control patients. Results: Overall sensitivity was 80.5% and specificity 89.8%, and was not greatly impacted by inflammation or infection. TERT remaining positive after initial surgery was associated with residual carcinoma in situ. TERT in urine was a reliable and dynamic predictor of recurrence in NMIBC (P
- Published
- 2017
9. Src tyrosine kinase inhibits apoptosis through the Erk1/2- dependent degradation of the death accelerator Bik
- Author
-
R Rimokh, G Gillet, Jonathan Lopez, Ivan Mikaelian, C Hesling, Julien Prudent, N Popgeorgiev, Philippe Gonzalo, and R Gadet
- Subjects
Programmed cell death ,MAP Kinase Signaling System ,MAP Kinase Kinase 2 ,MAP Kinase Kinase 1 ,Oncogene Protein p21(ras) ,Biology ,Inhibitor of apoptosis ,Mitochondrial Proteins ,Mice ,Cell Line, Tumor ,Neoplasms ,medicine ,Animals ,Humans ,Staurosporine ,Enzyme Inhibitors ,Molecular Biology ,Adaptor Proteins, Signal Transducing ,Mitogen-Activated Protein Kinase 1 ,Original Paper ,Mitogen-Activated Protein Kinase 3 ,Membrane Proteins ,Cell Biology ,Cell biology ,Enzyme Activation ,src-Family Kinases ,Proteasome ,Drug Resistance, Neoplasm ,Apoptosis ,Proteolysis ,NIH 3T3 Cells ,Cancer research ,Thapsigargin ,Phosphorylation ,raf Kinases ,Apoptosis Regulatory Proteins ,Tyrosine kinase ,medicine.drug ,Proto-oncogene tyrosine-protein kinase Src - Abstract
Src, the canonical member of the non-receptor family of tyrosine kinases, is deregulated in numerous cancers, including colon and breast cancers. In addition to its effects on cell proliferation and motility, Src is often considered as an inhibitor of apoptosis, although this remains controversial. Thus, whether the ability of Src to generate malignancies relies on an intrinsic aptitude to inhibit apoptosis or requires preexistent resistance to apoptosis remains somewhat elusive. Here, using mouse fibroblasts transformed with v-Src as a model, we show that the observed Src-dependent resistance to cell death relies on Src ability to inhibit the mitochondrial pathway of apoptosis by specifically increasing the degradation rate of the BH3-only protein Bik. This effect relies on the activation of the Ras–Raf–Mek1/2–Erk1/2 pathway, and on the phosphorylation of Bik on Thr124, driving Bik ubiquitylation on Lys33 and subsequent degradation by the proteasome. Importantly, in a set of human cancer cells with Src-, Kras- or BRAF-dependent activation of Erk1/2, resistances to staurosporine or thapsigargin were also shown to depend on Bik degradation rate via a similar mechanism. These results suggest that Bik could be a rate-limiting factor for apoptosis induction of tumor cells exhibiting deregulated Erk1/2 signaling, which may provide new opportunities for cancer therapies.
- Published
- 2012
10. Lithium suppresses motility and invasivity of v-src-transformed cells by glutathione-dependent activation of phosphotyrosine phosphatases
- Author
-
B D Néel, Jonathan Lopez, Germain Gillet, and A Chabadel
- Subjects
Cancer Research ,Lithium (medication) ,Blotting, Western ,Chick Embryo ,Protein tyrosine phosphatase ,Biology ,Chorioallantoic Membrane ,Oncogene Protein pp60(v-src) ,Mice ,Cell Movement ,Okadaic Acid ,Genetics ,medicine ,Animals ,Neoplastic transformation ,Enzyme Inhibitors ,Phosphorylation ,Molecular Biology ,Cell Proliferation ,Dose-Response Relationship, Drug ,Cell growth ,Wnt signaling pathway ,Neoplasms, Experimental ,Cell Transformation, Viral ,Glutathione ,Cell biology ,Enzyme Activation ,Microscopy, Fluorescence ,v-Src ,Lithium Compounds ,NIH 3T3 Cells ,Matrix Metalloproteinase 2 ,Protein Tyrosine Phosphatases ,Vanadates ,Signal transduction ,Lithium Chloride ,Reactive Oxygen Species ,Tyrosine kinase ,medicine.drug - Abstract
Lithium has long been used for the treatment and prophylaxis of bipolar mood disorder. However, nerve cells are not the sole targets of lithium. Indeed, lithium was reported to target numerous cell types, and affect cell proliferation, differentiation and death. Thus, the idea has been raised that lithium may act on signaling pathways involved in neoplastic transformation. Indeed, the effect of lithium on tumor progression is currently being tested in a limited number of clinical trials. However, the molecular mechanisms by which lithium affects neoplastic transformation remain to be characterized. Here, using mouse fibroblasts transformed by the v-src oncogene as a model, we show that lithium drastically inhibits cell motility and compromises the invasive phenotype of v-src-transformed cells. In addition, we show that this effect is mediated by the activation of phosphotyrosine phosphatases, but not by the direct inhibition of the v-Src tyrosine kinase. Finally, we show that lithium activates phosphotyrosine phosphatases by the modulation of the redox status of the cell, independently of the Wnt and the inositol phosphate canonical pathways. Thus, this study supports the idea that lithium, acting similar to an antioxydizer, may have antimetastatic properties in vivo.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.